BioNexus Gene Lab Corp. (NASDAQ:BGLC – Get Free Report) saw a significant drop in short interest in October. As of October 30th, there was short interest totaling 3,180 shares, a drop of 64.9% from the October 15th total of 9,051 shares. Based on an average daily trading volume, of 3,299 shares, the short-interest ratio is presently 1.0 days. Approximately 0.1% of the shares of the stock are short sold.
Analysts Set New Price Targets
Separately, Weiss Ratings lowered BioNexus Gene Lab from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, September 18th. One research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock has an average rating of “Sell”.
Read Our Latest Report on BGLC
BioNexus Gene Lab Stock Performance
BioNexus Gene Lab stock opened at $0.79 on Monday. BioNexus Gene Lab has a fifty-two week low of $0.81 and a fifty-two week high of $4.97. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.28 and a current ratio of 6.08. The stock has a market cap of $2.32 million, a P/E ratio of -0.63 and a beta of 4.28. The firm’s fifty day moving average price is $1.22 and its 200-day moving average price is $1.86.
BioNexus Gene Lab (NASDAQ:BGLC – Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.12) earnings per share for the quarter. The firm had revenue of $0.08 million for the quarter. BioNexus Gene Lab had a negative net margin of 82.38% and a negative return on equity of 32.92%.
BioNexus Gene Lab Company Profile
BioNexus Gene Lab Corp. is a Malaysia-focused company with businesses in medical diagnostics and chemical distribution. Through its laboratory operations, it provides molecular and genetic testing services to support healthcare assessment and decision-making. The company also distributes industrial and specialty chemicals through its subsidiary, Chemrex Corporation. Its products serve business customers in sectors that use chemicals in manufacturing and related applications. BioNexus Gene Lab’s operations are primarily based in Malaysia.
See Also
- Five stocks we like better than BioNexus Gene Lab
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
Receive News & Ratings for BioNexus Gene Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNexus Gene Lab and related companies with MarketBeat.com's FREE daily email newsletter.
